Abstract:Mateo Sanchis-Borja, 1 Florian Guisier, 2 Aurélie Swalduz, 3 Hubert Curcio, 4 Victor Basse, 5 Christophe Maritaz, 6 Christos Chouaid, 1 Jean-Bernard Auliac 1 1 Pulmonology Department, Créteil Intercommunal Hospital, Créteil, France; 2 Normandie Univ, UNIROUEN, LITIS Laboratory QuantIF team EA4108, CHU Rouen, Department of Pneumology and Inserm CIC-CRB 1404, Rouen, France; 3 Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France; 4 Department of Medical Oncology, Centre François Baclesse, Caen, France; 5 Department of Oncology CHU Morvan, Brest, France; 6 Medical Affairs Department, Oncology, Boehringer Ingelheim France, Paris, France Correspondence: Jean-Bernard Auliac, Pulmonology Department, Créteil Intercommunal Hospital, Créteil, France, Email Purpose: The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, is an effective first-line therapy for patients with common EGFR mutation-positive non-small cell lung cancer (NSCLC). However, almost all patients become resistant to treatment. In some patients, emergence of tertiary EGFR mutations is implicated as a resistance mechanism. This study describes patients with NSCLC who acquired the rare EGFR mutations, L718Q or G724S, following EGFR TKI treatment. Patients and Methods: This was a retrospective, observational study undertaken in France from Feb–Nov 2021, in patients with EGFR mutation-positive NSCLC with an acquired L718Q or G724S mutation. Primary objectives were description of tumor characteristics, progression, and progression under treatment. Results: Nine eligible patients were identified. Acquired resistance to initial EGFR TKI treatment was associated with T790M emergence in six patients, who then received osimertinib monotherapy. Overall, eight patients received osimertinib monotherapy treatment at some point (average treatment duration: 18.3 months). Following the emergence of L718Q or G724S, patients received chemotherapy (n = 4; two of whom subsequently received afatinib), nivolumab (n = 2), afatinib (n = 2), or immunochemotherapy (n = 1). In the four patients who received afatinib after identification of L718Q or G724S, 2 achieved a partial response, one had stable disease and one had progressive disease. Treatment duration was 1.6– 31.7 months. In patients with controlled disease (n = 3), progression-free survival was 6.1– 31.7 months. Two of these patients had previously received osimertinib. Conclusion: Currently, there is no consensus regarding the treatment of EGFR mutation-positive NSCLC following emergence of the osimertinib resistance mutations, L718Q or G724S. Afatinib appears to be a promising treatment option in this setting. Keywords: osimertinib, afatinib, real-world evidence, tertiary EGFR mutations Activating mutations in the epidermal growth factor receptor ( EGFR) gene are present in approximately 10–15% of Caucasian patients with advanced non-small cell lung cancer (NSCLC) of adenocarcinoma histology (11% in France), 1 rising to about 50% in Asian patients. 2 First-line standard of care for these patients comprises monotherapy with an EGFR tyrosine kinase inhibitor (TKI). Three generations of EGFR TKI are available which have different mechanisms of action; the first-generation reversible EGFR TKIs (erlotinib and gefitinib), the second-generation ErbB family blockers (afatinib and dacomitinib), and the third-generation irreversible EGFR TKI, osimertinib. 2 Head-to-head prospective trials have demonstrated the superiority of second- and third-generation TKIs over first-generation EGFR TKIs. 3–5 Based on the Phase III FLAURA trial, 4,6 which demonstrated overall survival (OS) benefit with osimertinib versus erlotinib/gefitinib and favorable tolerability, osimertinib is often used as treatment of choice for EGFR mutation-positive NSCLC. However, disease progression is ultimately inevitable. 7 Most randomized clinical trials of EGFR TKIs have been restricted to patients with so called "common" EGFR mutations, comprising deletions of exon 19 (Del19) and L858R in exon 21; these two mutations represent a large majority of the EGFR mutations detected. 8 Consequently, few prospective data are available to inform treatment decisions for the estimated 7–23% of EGFR mutation-positive NSCLC tumors that harbor uncommon EGFR mutations. 9 Uncommon EGFR mutations are highly heterogeneous. In silico and in vitro observations indicate that the sensitivity of -Abstract Truncated-

Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib

Gene Mutational Profiling Of Chinese Egfr-T790m Mutation Nsclc Patients Required Resistance To Osimertinib By Next Generation Sequencing

Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models

Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options

Potential Resistance Mechanisms Using Next Generation Sequencing from Chinese EGFR T790M+ Non-Small Cell Lung Cancer Patients with Primary Resistance to Osimertinib: A Multicenter Study

Post-Progression Analysis of EGFR-Mutant NSCLC Following Osimertinib Therapy in Real-World Settings

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib

Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer

1369P EGFR T790M Ctdna Abundance and TP53 Co-Mutation by Next Generation Sequencing Predicted Clinical Outcomes of Osimertinib in Non-Small Cell Lung Cancer Patients from a Real-World Study

Treatment Patterns and Clinical Outcomes in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer After Progression on Osimertinib

NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples

Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer

Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer

P1.13-18 Exploring the Resistance Mechanism of Osimertinib and Monitoring the Treatment Response Using Plasma Ctdna in Chinese NSCLC Patients

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms

Abstract 964: Updated results of a prospective observational multicenter study on resistance mechanisms to osimertinib using circulating tumor DNA analyses in EGFR-mutated non-small cell lung cancer patients (ELUCIDATOR study)

Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC

Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort

Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France